Vertex Pharmaceuticals Incorporated (VRTX) Q1 2011 Earnings Results

Vertex Pharmaceutica Misses on EPS, Stock Down 0.56%

The earnings report indicates that Vertex Pharmaceutica is still facing challenges, as reflected in the negative EPS. The stock's slight decline of 0.56% suggests that investors may be cautious about the company's current trajectory. The lack of revenue figures and guidance updates adds to the uncertainty surrounding future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.91	N/A	+13.74%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced in the quarter but remained focused on their strategic objectives. They emphasized the importance of innovation and pipeline development.

Management highlighted ongoing challenges in the current market environment.

They expressed commitment to long-term goals despite short-term setbacks.

Vertex Pharmaceutica Misses on EPS, Stock Down 0.56%

Key numbers

Management commentary

Vertex Pharmaceuticals Incorporated

More earnings this week

Vertex Pharmaceutica Misses on EPS, Stock Down 0.56%

Key numbers

Management commentary